Novel Therapeutic Approaches

作者: Sima S. Jeha , Laura L. Worth

DOI: 10.1007/978-0-387-24472-3_14

关键词:

摘要: During the latter part of twentieth century, substantial improvements were made in treatment childhood cancers. Fifty years ago, most pediatric cancers fatal. Today, however, more than 75% patients with cancer survive disease. Most advances have been achieved through extensive research and well-designed clinical trials. Investigators continue to explore novel therapies goals providing salvage whose disease does not respond current improving efficacy safety frontline regimens. Recent fields genetics, immunology, molecular biology led a better understanding cancers, which turn has rational design drugs based on thorough targets or inside malignant cells. Such an approach aims further improve cure rates reduce toxicity. This chapter describes available at M. D. Anderson Cancer Center. We describe difficulties conducting innovative children as well how multidisciplinary interactions help quickly safely benefit from therapies, including stem cell transplantation for leukemia, lymphoma, other solid tumors.

参考文章(14)
N Apisarnthanarax, M Donato, M Körbling, D Couriel, J Gajewski, S Giralt, I Khouri, C Hosing, R Champlin, M Duvic, P Anderlini, Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplantation. ,vol. 31, pp. 459- 465 ,(2003) , 10.1038/SJ.BMT.1703871
DR Couriel, K Hicks, R Saliba, A Cohen, C Ippoliti, Y Hsu, M Donato, S Giralt, I Khouri, C Hosing, MJ De Lima, B Andersson, J Gajewski, J Neumann, R Champlin, None, 15 Sirolimus (rapamycin) for treatment of steroid-refractory chronic graft versus host disease Biology of Blood and Marrow Transplantation. ,vol. 9, pp. 67- 68 ,(2003) , 10.1016/S1083-8791(03)80016-2
Rosemary Roberts, William Rodriguez, Dianne Murphy, Terrie Crescenzi, Pediatric Drug Labeling JAMA. ,vol. 290, pp. 905- 911 ,(2003) , 10.1001/JAMA.290.7.905
D.R. Couriel, K. Hicks, S. Giralt, C. Ippoliti, I. Khouri, Lima M. de, E. Horton, A. Cohen, C. Hosing, M. Donato, P. Anderlini, J.J. Molldrem, J. Gajewski, R. Champlin, 102Phase III trial with infliximab/methylprednisolone (MP) vs MP for the treatment of acute GVHD: Preliminary findings Biology of Blood and Marrow Transplantation. ,vol. 9, pp. 95- ,(2003) , 10.1016/S1083-8791(03)80103-9
B. Sleight, K. Chan, A. Serrano, A. Gilman, 104Infliximab for GVHD therapy in children Biology of Blood and Marrow Transplantation. ,vol. 9, pp. 96- ,(2003) , 10.1016/S1083-8791(03)80105-2
D Przepiorka, D Blamble, S Hilsenbeck, M Danielson, R Krance, KW Chan, Tacrolimus clearance is age-dependent within the pediatric population. Bone Marrow Transplantation. ,vol. 26, pp. 601- 605 ,(2000) , 10.1038/SJ.BMT.1702588
John C. Somberg, Pediatric drug development. American Journal of Therapeutics. ,vol. 10, pp. 2- 2 ,(2003) , 10.1097/00045391-200301000-00002
Gregory H. Reaman, Pediatric oncology: current views and outcomes Pediatric Clinics of North America. ,vol. 49, pp. 1305- 1318 ,(2002) , 10.1016/S0031-3955(02)00102-5
Katarina Aleksa, Gideon Koren, Ethical Issues in Including Pediatric Cancer Patients in Drug Development Trials Pediatric Drugs. ,vol. 4, pp. 257- 265 ,(2002) , 10.2165/00128072-200204040-00005
Sima Jeha, Varsha Gandhi, Ka Wah Chan, Lisa McDonald, Irma Ramirez, Renee Madden, Michael Rytting, Mark Brandt, Michael Keating, William Plunkett, Hagop Kantarjian, Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. ,vol. 103, pp. 784- 789 ,(2004) , 10.1182/BLOOD-2003-06-2122